Health Canada’s consultation on new health-related labelling for tobacco products
https://policybase.cma.ca/link/policy13939

POLICY TYPE                   Response to consultation
DATE                          2018-12-14
TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE  Response to consultation
DATE  2018-10-02
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE  Response to consultation
DATE  2018-09-06
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

Policy Type: Response to consultation
Date: 2018-04-23
Topics: Health care and patient safety

Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear [Recipient],

The Canadian Medical Association (CMA) recognises that the opportunity to provide comments on the proposed Front of Package (FOP) labelling regulation is an important opportunity to send a message that will have a significant impact on public health and patient safety.

The CMA understands that the objective of the proposed FOP labelling regulation is to provide information to the public to assist in making informed decisions about the risks and benefits of a medication. It is important to note that the proposed FOP labelling regulation is intended to augment, not replace, the information provided on the back of the package. The CMA supports the inclusion of non-compliance information on the back of the package, including a clear explanation of what the non-compliance means for patients and health care providers.

The CMA believes that the proposed FOP labelling regulation is an important step in addressing the issue of medication safety. It is important to note that the proposed FOP labelling regulation is intended to augment, not replace, the information provided on the back of the package. The CMA supports the inclusion of non-compliance information on the back of the package, including a clear explanation of what the non-compliance means for patients and health care providers.

The CMA appreciates the opportunity to provide comments on the proposed FOP labelling regulation. The CMA encourages the federal government to consider the comments provided by the CMA in developing the final regulations and to continue to engage with stakeholders to ensure that the FOP labelling regulation meets the needs of all Canadians.

Sincerely,

[Signature]

[Name]

[Title]

[Contact Information]
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents